The DOI matches its OpenAlex record; 5 of the 5 references it cites were found in a registry or an index.
Myc confers androgen-independent prostate cancer cell growth
Open accessAbstract
Prostate cancer is one of the most diagnosed and mortal cancers in western countries. A major clinical problem is the development of androgen-independent prostate cancer (AIPC) during antihormonal treatment. The molecular mechanisms underlying the change from androgen dependence to independence of these tumors are poorly understood and represent a challenge to develop new therapies. Based on genetic data showing amplification of the c-myc gene in AIPC, we studied the ability of c-myc to confer AIPC cell growth. Human androgen-dependent prostate cancer cells overexpressing c-myc grew independently of androgens and presented tumorigenic properties in androgen-depleted conditions. Analysis of signalling pathways by pharmacological inhibitors of the androgen receptor (AR) or by RNA interference directed against AR or c-myc showed that c-myc acted downstream of AR through multiple growth effectors. Thus c-myc is required for androgen-dependent growth and following ectopic expression can induce androgen-independent growth. Moreover, RNA interference directed against c-myc showed that growth of human AIPC cells, AR-positive or -negative, required c-myc expression. Furthermore, we showed that c-myc-overexpressing cells retain a functional p53 pathway and thus respond to etoposide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., & Green, D. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80054-4 · Cited by 721
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
A history of prostate cancer treatment.
Denmeade, S. R., & Isaacs, J. T. (2002) · Nature reviews. Cancer · doi:10.1038/nrc801 · Cited by 591
Wright, M. E., Tsai, M.-J., & Aebersold, R. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0031 · Cited by 166
Research works printed but not linked: 35
- Craft, 1999, Nat. Med., 5, 280, 10.1038/6495 · DOI · Paper page
- Taplin, 1999, Cancer Res., 59, 2511
- Zhao, 2000, Nat. Med., 6, 703, 10.1038/76287 · DOI · Paper page
- Edwards, 2001, BJU Int., 88, 633, 10.1046/j.1464-410X.2001.02350.x · DOI
- Marcelli, 2000, Cancer Res., 60, 944
- Savinainen, 2002, Am. J. Pathol., 160, 339, 10.1016/S0002-9440(10)64377-5 · DOI
- Signoretti, 2000, J. Natl. Cancer Inst., 92, 1918, 10.1093/jnci/92.23.1918 · DOI · Paper page
- Nupponen, 1998, Am. J. Pathol., 153, 141, 10.1016/S0002-9440(10)65554-X · DOI · Paper page
- Visakorpi, 1995, Cancer Res., 55, 342
- Kaltz-Wittmer, 2000, Lab. Invest., 80, 1455, 10.1038/labinvest.3780152 · DOI
- Nesbit, 1999, Oncogene., 18, 3004, 10.1038/sj.onc.1202746 · DOI · Paper page
- Wang, 1998, Genes Dev., 12, 1769, 10.1101/gad.12.12.1769 · DOI · Paper page
- Wolf, 1992, Mol. Endocrinol., 6, 753, 10.1210/me.6.5.753 · doi:10.1210/me.6.5.753
- Ahlgren, 2000, Prostate., 42, 274, 10.1002/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R · doi:10.1002/(sici)1097-0045(20000301)42:4<274::aid-pros4>3.0.co;2-r
- Ismail, 2002, Prostate., 51, 117, 10.1002/pros.10066 · doi:10.1002/pros.10066
- Goodrich, 1992, Nature., 360, 177, 10.1038/360177a0 · DOI
- Vlach, 1996, EMBO J., 15, 6595, 10.1002/j.1460-2075.1996.tb01050.x · DOI · Paper page
- Carrano, 1999, Nat. Cell Biol., 1, 193, 10.1038/12013 · DOI · Paper page
- Hermeking, 2000, Proc. Natl. Acad. Sci. U. S. A., 97, 2229, 10.1073/pnas.050586197 · DOI · Paper page
- Mateyak, 1999, Mol. Cell. Biol., 19, 4672, 10.1128/MCB.19.7.4672 · DOI · Paper page
- Bello-Fernandez, 1993, Proc. Natl. Acad. Sci. U. S. A., 90, 7804, 10.1073/pnas.90.16.7804 · DOI · Paper page
- Berns, 2000, Oncogene., 19, 3330, 10.1038/sj.onc.1203639 · DOI
- Ge, 2000, Int. J. Cancer., 86, 155, 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M · DOI
- Eagle, 1995, Nat. Genet., 9, 249, 10.1038/ng0395-249 · DOI · Paper page
- Yeh, 1999, Proc. Natl. Acad. Sci. U. S. A., 96, 5458, 10.1073/pnas.96.10.5458 · DOI · Paper page
- Quarmby, 1987, Mol. Endocrinol., 1, 865, 10.1210/mend-1-12-865 · DOI
- Ling, 2001, J. Endocrinol., 170, 287, 10.1677/joe.0.1700287 · DOI
- Asadi, 1995, Int. Urol. Nephrol., 27, 67, 10.1007/BF02575223 · doi:10.1007/bf02575223
- Silva, 2001, Endocr. Res., 27, 153, 10.1081/ERC-100107177 · DOI
- Zhang, 2000, Prostate., 43, 278, 10.1002/1097-0045(20000601)43:4<278::AID-PROS7>3.0.CO;2-4 · doi:10.1002/1097-0045(20000601)43:4<278::aid-pros7>3.0.co;2-4
- Brown, 2002, J. Pathol., 198, 237, 10.1002/path.1206 · DOI
- Linja, 2001, Cancer Res., 61, 3550
- Miyoshi, 2000, Prostate., 43, 225, 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7 · doi:10.1002/(sici)1097-0045(20000515)43:3<225::aid-pros9>3.0.co;2-7
- Sasaki, 2002, J. Natl. Cancer Inst., 94, 384, 10.1093/jnci/94.5.384 · DOI · Paper page
- Miyoshi, 2001, BJU Int., 88, 982, 10.1046/j.1464-4096.2001.00936.x · DOI
Cited by
The evolutionary history of lethal metastatic prostate cancer
ICGC Prostate UK Group, Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E., Brewer, D. S., Kallio, H. M. L., Högnäs, G., et al. (2015) · Nature · doi:10.1038/nature14347 · Cited by 1,388
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Wu, Y.-M., Cieślik, M., Lonigro, R. J., Vats, P., Reimers, M. A., Cao, X., Ning, Y., Wang, L., Kunju, L. P., de Sarkar, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.034 · Cited by 598
Sharma, N. L., Massie, C. E., Ramos-Montoya, A., Zecchini, V., Scott, H. E., Lamb, A. D., MacArthur, S., Stark, R., Warren, A. Y., Mills, I. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.010 · Cited by 405
A long noncoding RNA connects c-Myc to tumor metabolism
Hung, C.-L., Wang, L.-Y., Yu, Y.-L., Chen, H.-W., Srivastava, S., Petrovics, G., & Kung, H.-J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415669112 · Cited by 302
Zadra, G., Ribeiro, C. F., Chetta, P., Ho, Y., Cacciatore, S., Gao, X., Syamala, S., Bango, C., Photopoulos, C., Huang, Y., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808834116 · Cited by 291
The oncogene ERG: a key factor in prostate cancer
Adamo, P., & Ladomery, M. R. (2016) · Oncogene · doi:10.1038/onc.2015.109 · Cited by 275
Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities
Vashchenko, N., & Abrahamsson, P.-A. (2005) · European Urology · doi:10.1016/j.eururo.2004.09.007 · Cited by 260
González‐Sarrías, A., Giménez‐Bastida, J. A., García‐Conesa, M. T., Gómez‐Sánchez, M. B., García‐Talavera, N. V., Gil‐Izquierdo, A., Sánchez‐Álvarez, C., Fontana‐Compiano, L. O., Morga‐Egea, J. P., Pastor‐Quirante, F. A., et al. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900152 · Cited by 212
Carabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172
USP22 regulates oncogenic signaling pathways to drive lethal cancer progression
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1954 · Cited by 126
Regulation of ploidy and senescence by the AMPK‐related kinase NUAK1
Humbert, N., Navaratnam, N., Augert, A., Da Costa, M., Martien, S., Wang, J., Martinez, D., Abbadie, C., Carling, D., de Launoit, Y., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.342 · Cited by 115
Self-citationImmortalization of primary human prostate epithelial cells by c-Myc
Gil, J., Kerai, P., Lleonart, M., Bernard, D., Cigudosa, J. C., Peters, G., Carnero, A., & Beach, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-4030 · Cited by 105
Self-citationc-MYC-Induced Sebaceous Gland Differentiation Is Controlled by an Androgen Receptor/p53 Axis
Cottle, D. L., Kretzschmar, K., Schweiger, P. J., Quist, S. R., Gollnick, H. P., Natsuga, K., Aoyagi, S., & Watt, F. M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.013 · Cited by 80
McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0123 · Cited by 78
THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer
Blomme, A., Peter, C., Mui, E., Rodriguez Blanco, G., An, N., Mason, L. M., Jamieson, L. E., McGregor, G. H., Lilla, S., Ntala, C., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114764 · Cited by 36
CUL4B/miR‐33b/C‐MYC axis promotes prostate cancer progression
Zhao, M., Qi, M., Li, X., Hu, J., Zhang, J., Jiao, M., Bai, X., Peng, X., & Han, B. (2019) · The Prostate · doi:10.1002/pros.23754 · Cited by 32
Hwang, J. H., Arafeh, R., Seo, J.-H., Baca, S. C., Ludwig, M., Arnoff, T. E., Sawyer, L., Richter, C., Tape, S., Bergom, H. E., et al. (2022) · eLife · doi:10.7554/elife.73223 · Cited by 26
Metadata
- Authors
- Bernard, D., Pourtier, A., Gil, J., & Beach, D.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-12-01
- Volume
- 112
- Issue
- 11
- Pages
- 1724-1731
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4235592864
- Cited by
- 224
- References
- 5
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.